The second objective was to compare the determination of NfL in CSF and S, using a highly sensitive ELISA method, with the routine neurodegeneration biomarkers measured in Alzheimer’s disease (AD), and to study their concentrations relative to the degree of cognitive deficit among patients with neurodegenerative diseases. The gene discussed is NEFL; the disease is Cognitive impairment.